A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma.

At a glance

Drugs Pimasertib (Primary) ; Dacarbazine
Indications Malignant melanoma; Skin cancer
Focus Therapeutic Use
Sponsors EMD Serono; Merck Serono

Most Recent Events

31 Aug 2018 Biomarkers information updated
11 Oct 2016 Primary endpoint (Progression-free survival) has been met, according to results presented at the 41st European Society for Medical Oncology Congress.
11 Oct 2016 Results assessing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight

A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma.

A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma.

At a glance

Most Recent Events

Table of Contents

About Our Content

Other Sites

Help & Contacts

Downloads

Legal